However, in esophageal carcinoma, ovarian serous cystadenocarcinoma, lung squamous cell carcinoma, and breast invasive carcinoma, more than 2% of cases had amplifications of CXCR2 ligand genes (Table 20). This evidence concerns the gene CXCR2 and squamous cell lung carcinoma.